NZ758917A - Compounds for positron emission tomography - Google Patents
Compounds for positron emission tomographyInfo
- Publication number
- NZ758917A NZ758917A NZ758917A NZ75891714A NZ758917A NZ 758917 A NZ758917 A NZ 758917A NZ 758917 A NZ758917 A NZ 758917A NZ 75891714 A NZ75891714 A NZ 75891714A NZ 758917 A NZ758917 A NZ 758917A
- Authority
- NZ
- New Zealand
- Prior art keywords
- radical
- radionuclide
- compounds
- positron emission
- emission tomography
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002600 positron emission tomography Methods 0.000 title abstract 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 102000035029 vitamin receptors Human genes 0.000 abstract 1
- 108091005463 vitamin receptors Proteins 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904400P | 2013-11-14 | 2013-11-14 | |
| US201361904387P | 2013-11-14 | 2013-11-14 | |
| US201361909822P | 2013-11-27 | 2013-11-27 | |
| NZ719939A NZ719939B2 (en) | 2013-11-14 | 2014-11-13 | Compounds for positron emission tomography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ758917A true NZ758917A (en) | 2022-02-25 |
Family
ID=80679540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ758917A NZ758917A (en) | 2013-11-14 | 2014-11-13 | Compounds for positron emission tomography |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ758917A (en) |
-
2014
- 2014-11-13 NZ NZ758917A patent/NZ758917A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014611A (en) | Compounds for positron emission tomography. | |
| MX2021008977A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. | |
| MX2018008168A (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy. | |
| MX2022002401A (en) | Radiopharmaceuticals, radioimaging agents, and uses thereof. | |
| MX2015008993A (en) | Triazine based radiopharmaceuticals and radioimaging agents. | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201890915A1 (en) | CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA | |
| MX2017003886A (en) | Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells. | |
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| MX2015011830A (en) | Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors. | |
| MX343405B (en) | Alpha-emitting complexes. | |
| NZ739770A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| EA201890221A1 (en) | HBED BISPHOSPHONATE, THEIR CONJUGATES WITH RADIOMETAL AND THEIR USE AS MEDICAL TREATMENT DIAGNOSTIC AGENTS | |
| MX2013012793A (en) | Radiolabeled amino acids for diagnostic imaging. | |
| PH12020551471A1 (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
| MX2019001053A (en) | Chelated psma inhibitors. | |
| MX2016003725A (en) | Compounds and their use for preparation of tau imaging agents and tau imaging formulations. | |
| MX2013012795A (en) | Novel precursors of glutamate derivatives. | |
| NZ758917A (en) | Compounds for positron emission tomography | |
| WO2013113801A3 (en) | Chelating agents | |
| EA202090575A3 (en) | CONNECTIONS FOR POSITRON EMISSION TOMOGRAPHY | |
| NZ708849A (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
| MX336322B (en) | 99mtc-edda/hynic-ggc-aunp-mannose as a radiopharmaceutical for the detection of the sentinel node in breast cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2023 BY COMPUTER PACKAGES INC Effective date: 20221017 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2024 BY COMPUTER PACKAGES INC Effective date: 20231230 |